The CRISPR Conundrum: A Pioneering Gene Therapy Paused by Unexpected Risk

A CRISPR Conundrum: Intellia's Trial Halt Jolts the Biotech World

The CRISPR Horizon: Intellia's Bold Leap Into Our Genetic Future, One Edit at a Time

Biotech's Pulse: Gene-Editing's Leap, Cancer's New Fights, and What's Stirring the Industry

The Shaking Ground: Intellia's Gene-Editing Dream Hits a Harsh Reality Check with Trial Setback

Midday Market Movers: Biotech Rockets, Tech Soars, and a Coffee Giant Stumbles

Cathie Wood's ARK Invest Stacks Up on Alibaba, Baidu, and Biotech Gems in Active Week